Wednesday, 13 July 2016
AVIPERO Issued Key US patent on the Utility of Beta1 Integrin.
EDINBURGH, SCOTLAND-Wed, 13 July, 2016—–AVIPERO (Registered in Scotland SC353945) announced today that it has been issued the US patent from the USPTO titled “Tissue Repair by Modulation of Beta-1 Integrin Biological Function” claiming use of beta1 integrin for tissue repair. The patent was granted on the above mentioned application on 5 July 2016 having the patent no. 9,382,322. The patent will remain in force until 2025.
Tuesday, 20 October 2015
AVIPERO (Registered in Scotland SC353945) announced today the first successful results from the Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) on anti-infectives.
Under the collaboration, USAMRIID and Avipero jointly established a research program focused on emerging viral infections. The results showed positive anti-viral activity of a novel therapeutic strategy against Ebola by targeting host mechanisms utilised by the Ebola virus. The strategy entailed a combination of an antibody against the cell adhesion receptor, beta1 integrin, and a derivative of the marketed cholesterol-lowering drug ezetimibe. The treatment combination demonstrated synergistic mode of action reducing viremia by 80% in cell culture models. The treatment showed no toxicity.
Monday, 19 May 2014
Fusion Antibodies to Humanize Avipero’s integrin antibody platform.
EDINBURGH, SCOTLAND- Monday, 19th May, 2014—– Fusion Antibodies Ltd has today announced a collaboration with the regenerative medicine company Avipero Ltd for humanization of their integrin antibody platform. The antibody engineering and humanization program partnered with Fusion Antibodies relates to the humanization of beta integrin targeting antibodies under development by Avipero for tissue repair and viral infections.
Monday, 14 April 2014
AVIPERO Appoints Dr. Samuel Asculai as Senior Advisor
EDINBURGH, SCOTLAND- Monday, 14th April, 2014—–The board of AVIPERO (Registered in Scotland SC353945) announced today the appointment of Dr. Samuel Asculai as a Senior Advisor. Dr Asculai is a senior executive with over 30 years of cross-functional experience in the pharmaceutical, chemical and biotechnology industries.
Friday, 17 January 2014
AVIPERO Receives Notice of Allowance for Key Patent from the U.S. Patent Office
EDINBURGH, SCOTLAND-Friday, 17 January, 2014—–The board of AVIPERO (Registered in Scotland SC353945) announced today announced that it has received a Notice of Allowance from the U.S. Patent Office for its “COMPOUNDS AND METHODS FOR THE MODULATION OF BETA-1 INTEGRIN FUNCTION TO MEDIATE TISSUE REPAIR ” (serial number 12/528,749) patent application.
Monday, 6 January 2014
AVIPERO and Public Health England Announce R&D Collaboration Agreement In Anti-infectives.
EDINBURGH, SCOTLAND-Mon, 6 January, 2014—–The board of AVIPERO (Registered in Scotland SC353945) announced today the formation of joint research and development (R&D) collaboration with Public Health England (PHE) in anti-infectives. The collaboration is effective immediately.
Friday, 18 October, 2013
John Blenkinsopp appointed as Chief Medical Officer of AVIPERO
EDINBURGH, SCOTLAND-Fri, 18 October, 2013—–The board of AVIPERO (Registered in Scotland SC353945) announced today Dr. John Blenkinsopp has been appointed as Chief Medical Officer. John studied Pharmacy at Bradford University and Medicine at Birmingham University. He has postgraduate qualifications in both management and Pharmaceutical Medicine. John has worked in all phases of drug development. He was a Clinical Research Physician at Hazleton Medical Research Unit (now Covance), Leeds, UK, a Phase 1 clinical research unit with 50 beds and over 40 studies completed each year. He has also worked for AstraZeneca, GlaxoSmithKline and Schering Plough.
Tuesday, 28 May, 2013
Graham Bell appointed as CEO of AVIPERO.
EDINBURGH, SCOTLAND-Tue, 28 May, 2013—–The board of AVIPERO (Registered in Scotland SC353945) announced today Dr. Graham Bell has been appointed as Chief Executive Officer. Graham has over 25 years experience working in SME in UK, in drug development, business and corporate development roles. Dr Bell is a recognized authority in stratified medicine, having recently served as the Lead Specialist with the UK government’s Technology Strategy Board (TSB), Stratified Medicine Innovation Platform. He developed the strategy for future Government investments (up to £50m of TSB investment plus partner organisation investments) and formulated a technology roadmap along with UK stakeholders.
Monday, 2 July 2012
AVIPERO Issued 2 major UK Patents on targeting Beta1 Integrin for Tissue Repair and Related Methods.
EDINBURGH, SCOTLAND——AVIPERO (Registered in Scotland SC353945) announced today that it has been issued a major Japanese Patent Application in addition to two patents from the U.K. Intellectual Property Office. The Japanese patent covers utility of beta1 integrin in tissue repair. The UK patents cover claims of methods for use of beta1 integrin for tissue repair AND assay methods for identifying compounds targeting beta1 integrin for use in tissue repair. The Japanese patent No 2006-534832 have priority date of 17th October, 2003. The UK GB2478082 and GB2460009 have priority date of 26 February, 2007 and will remain in force until 26 February 2028.
17 November 2011 AVIPERO announces JB1a reverses tissue damage and induces tissue repair in emphysema.
EDINBURGH, SCOTLAND——AVIPERO (Registered in Scotland SC353945) announced today the results of its first R&D therapeutic platform in non-stem cell tissue repair and regeneration. The principal candidate, JB1a, is an antibody targeting the cell surface adhesion receptor beta1 integrin.